GlassScriptPhysician profile
Maryamnaz Zaribaf
NPI 1336672666
$1,360.05
in general payments reported to CMS, 2019-2025
18 companies · $781 in 2025
The $781 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $102 · 2024: $477 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,335 · Travel and Lodging: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,335.05 |
| Travel and Lodging | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.72 | 2023-2025 | |
| Medtronic, INC. | $235.11 | 2025 | Percept PC Brainsense |
| Teva Pharmaceuticals USA, INC. | $118.97 | 2024-2025 | Austedo Xr, Austedo Xr |
| Amneal Pharmaceuticals LLC | $76.58 | 2023-2024 | Rytary, Crexont |
| Lilly USA, LLC | $72.01 | 2024 | Amyvid, Reyvow, Emgality |
| Biogen, INC. | $71.35 | 2024-2025 | Vumerity, Tysabri, Leqembi |
| Lundbeck LLC | $63.10 | 2025 | Rexulti |
| Pfizer INC. | $54.13 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $36.98 | 2025 | |
| Ge Healthcare | $32.76 | 2025 | |
| Kyowa Kirin, INC. | $32.32 | 2024 | Nourianz |
| Abbott Laboratories | $27.33 | 2025 | Infinity |
| Vanda Pharmaceuticals INC. | $23.09 | 2024 | Ponvory |
| Acadia Pharmaceuticals INC | $22.93 | 2025 | Nuplazid |
| Eisai INC. | $22.18 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $20.72 | 2025 | Gamunex-C |
| Catalyst Pharmaceuticals, INC. | $19.99 | 2024 | |
| Neurelis, INC. | $19.78 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryamnaz Zaribaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.